Bile acid malabsorption: colesevelam

References

Bristol-Myers Squibb Holdings Limited (2012) Questran powder for oral suspension 4 g: summary of product characteristics [online; accessed 18 September 2013]

European Medicines Agency (2012) Cholestagel: summary of product characteristics [online; accessed 18 September 2013]

General Medical Council (2013) Prescribing guidance: prescribing unlicensed medicines [online; accessed 18 September 2013]

Health and Social Care Information Centre (2013) Prescription cost analysis England 2012. [online; accessed 18 September 2013]

MIMS (2013) Colestid [online; accessed 18 September 2013]

National Institute for Health and Clinical Excellence (2012) SeHCAT (Tauroselcholic [⁷⁵Selenium] acid) for the investigation of bile acid malabsorption (BAM) and measurement of bile acid pool loss. NICE diagnostics guidance 7

NHS Business Services Authority (2013) Drug Tariff [online; accessed 18 September 2013]

Odunsi-Shiyanbade ST, Camilleri M, McKinzie S et al. (2010) Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clinical Gastroenterology and Hepatology 8: 159−65

Pharmacia Limited (2008) Colestid granules for oral suspension: summary of product characteristics [online; accessed 18 September 2013]

Puleston J, Morgan H, Andreyev J (2005) New treatment for bile salt malabsorption. Gut 54: 441−2

Sanofi (2012) Cholestagel: summary of product characteristics [online; accessed 18 September 2013]

Wedlake L, Thomas K, Lalji A et al. (2009) Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clinical Therapeutics 31: 2549−58